Roche Venture Fund

Corporate VC · Basel (Switzerland)

Corporate VC

Seed

Series B

Cloud/SaaS

Hardware

Sign up free to access full profile and submit your pitch.

About

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI).

Investment Criteria

Other investors that have backed the same portfolio companies as Roche Venture Fund. Expand any entry to see the shared portfolio companies.

• Novartis Venture Fund

  6 shared

  Shared portfolio companies

  • AlloCyte Pharmaceuticals AG
  • Freenome Holdings, Inc.
  • Rein Therapeutics Inc.
  • Soteria Biotherapeutics, Inc.
  • Splice Bio
  • Vivet Therapeutics SAS
• 5AM Ventures

  5 shared

  Shared portfolio companies

  • BlueLight Therapeutics Inc.
  • Enliven Therapeutics, Inc.
  • Entrada Therapeutics, Inc.
  • GlycoEra AG
  • Soteria Biotherapeutics, Inc.
• RA Capital Management

  5 shared

  Shared portfolio companies

  • C4 Therapeutics, Inc.
  • Enliven Therapeutics, Inc.
  • Freenome Holdings, Inc.
  • Pandion Operations, Inc.
  • Tango Therapeutics, Inc.
• SR One

  5 shared

  Shared portfolio companies

  • Arch Oncology, Inc.
  • Mission Therapeutics Ltd.
  • Pandion Operations, Inc.
  • Rein Therapeutics Inc.
  • River 3 Renal Corp.
• Bain Capital Life Sciences

  4 shared

  Shared portfolio companies

  • C4 Therapeutics, Inc.
  • Freenome Holdings, Inc.
  • River 3 Renal Corp.
  • Tango Therapeutics, Inc.
• Novo Holdings

  4 shared

  Shared portfolio companies

  • Arch Oncology, Inc.
  • Corvus Pharmaceuticals, Inc.
  • GlycoEra AG
  • NMD Pharma A/S
• OrbiMed

  4 shared

  Shared portfolio companies

  • Corvus Pharmaceuticals, Inc.
  • Enliven Therapeutics, Inc.
  • Kumquat Biosciences Inc.
  • Pandion Operations, Inc.
• Sofinnova Partners

  4 shared

  Shared portfolio companies

  • Enthera S.r.l.
  • GlycoEra AG
  • Mironid Limited
  • Mission Therapeutics Ltd.
• Agent Capital

  3 shared

  Shared portfolio companies

  • Entrada Therapeutics, Inc.
  • Freenome Holdings, Inc.
  • GlycoEra AG
• HBM Partners AG

  3 shared

  Shared portfolio companies

  • Freenome Holdings, Inc.
  • River 3 Renal Corp.
  • Viridian Therapeutics, Inc.